Phase 1 Pancreatic Cancer Trial, Recruiting NCT05779917 Sponsor: Second Affiliated Hospital of Guangzhou Medical University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 1 Pancreatic Cancer Trial, Recruiting

NCT05779917
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have advanced cancer where the tumour cells carry a protein called Mesothelin.
  • People who are expected to live for more than 12 weeks.
  • People whose heart, lungs, liver, kidneys, and blood are all functioning well enough to meet the trial's requirements.
  • People whose own immune cells (T cells) have been successfully modified in the lab to meet specific activity levels required by the trial (confirm with trial site for full technical details).
  • People who have read, understood, and signed the informed consent form, or whose legal guardian has done so on their behalf.

Who may not be able to join:

  • People who have previously received gene therapy of any kind.
  • People with a serious viral infection, such as hepatitis B, hepatitis C, or HIV.
  • People who have a known positive HIV diagnosis.
  • People who currently have an active infection caused by bacteria, viruses, fungi, or similar.
  • People who are pregnant or currently breastfeeding.
  • People who are taking systemic steroid medications at or above a certain daily dose (confirm the exact dose threshold with the trial site).
  • People with other serious medical conditions that the trial investigators consider unsuitable for participation.
  • People with any other circumstances that the trial investigators consider unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhenfeng Zhang, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University

Phone: 0086-020-39195965

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
10 March 2023
Est. completion
10 March 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of Patients with Dose Limiting Toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov